Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.70 |
| ▸ | TGM1 | P22735 | 10/20 | 0.70 |
| ▸ | F13A1 | P00488 | 9/20 | 0.70 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1872113 | 0.91 | TGM2 (0.67) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL26104923 | 0.91 | TGM2 (0.67) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL17277447 | 0.91 | TGM2 (0.69) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL5253097 | 0.91 | POLB (0.71) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL4235140 | 0.91 | TGM2 (0.67) | TGM2TGM1F13A1TGM3KMT2A | |
| SCHEMBL3971768 | 0.91 | TGM2 (0.69) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL1871457 | 0.88 | ALDH1A1 (0.70) | TGM2TGM1F13A1TGM3KMT2A | |
| SCHEMBL12061638 | 0.88 | TGM2 (0.63) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL932229 | 0.86 | TGM2 (0.63) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL25381627 | 0.86 | TGM2 (0.76) | TGM2TGM1F13A1TGM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | TGM2 593/4885TGM1 452/4885F13A1 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.